Mike Freedman, MD, MPhil is Oura’s Clinical Director of Heart Health, where he leads the strategic vision for cardiovascular health experiences across product, science, and clinical research. Dr. Freedman bridges the gap between complex cardiovascular pathophysiology and digital innovation to ensure Oura’s heart health capabilities are scientifically rigorous, trusted, and deeply human-centered. Before joining Oura, Dr. Freedman led Clinical Innovation for the Digital Health Team at Samsung Research America. In this role, he directed cross-functional digital health R&D strategy and clinical evidence, guiding a diverse portfolio focused on cardiac health and other domains. His work applied a clinical lens across all aspects of the R&D pipeline, including designing sensors and large-scale clinical studies, and establishing rigorous framework requirements for algorithm and AI endpoints. Prior to his medical training, Dr Freedman built epidemiologic and health economics and outcomes research (HEOR) models driving strategic decisions for large health organizations such as the Bill & Melinda Gates Foundation, Roche/Genentech, and the Centers for Disease Control and Prevention. Dr. Freedman continues to practice medicine at Stanford University School of Medicine and Lucile Packard Children’s Hospital, where he cares for patients in the cardiovascular intensive care unit (CVICU). He holds four undergraduate degrees from the University of Pittsburgh. He earned an MPhil in Bioscience Enterprise from the University of Cambridge as a Whitaker Fellow, and received his Medical Doctorate (MD) with distinction in Clinical & Translational Research from UCSF. Dr. Freedman completed his pediatric residency training at UPMC Children’s Hospital of Pittsburgh, followed by a pediatric critical care medicine fellowship and an NLM postdoctoral fellowship in biomedical informatics at Stanford University.